[1] R.L. Siegel, K.D. Miller, S.A. Fedewa, D.J. Ahnen, R.G.S. Meester, A. Barzi, A. Jemal, Colorectal cancer statistics, 2017, CA: A Cancer Journal for Clinicians, 67 (2017) 177-193.
[2] M. Arnold, M.S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global patterns and trends in colorectal cancer incidence and mortality, Gut, 66 (2017) 683-691.
[3] E. Van Cutsem, A. Cervantes, B. Nordlinger, D. Arnold, Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology, 25 (2014) iii1-iii9.
[4] M.G. Fakih, Metastatic Colorectal Cancer: Current State and Future Directions, Journal of Clinical Oncology, 33 (2015) 1809-1824.
[5] H. Ling, K. Pickard, C. Ivan, C. Isella, M. Ikuo, R. Mitter, R. Spizzo, M.D. Bullock, C. Braicu, V. Pileczki, The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis, Gut, 65 (2016) 977-989.
[6] Z. Obermeyer, E.J. Emanuel, Predicting the future—big data, machine learning, and clinical medicine, The New England journal of medicine, 375 (2016) 1216.
[7] A.M. Bur, M. Shew, J. New, Artificial intelligence for the otolaryngologist: a state of the art review, Otolaryngology–Head and Neck Surgery, 160 (2019) 603-611.
[8] J.T. Senders, P.C. Staples, A.V. Karhade, M.M. Zaki, W.B. Gormley, M.L.D. Broekman, T.R. Smith, O. Arnaout, Machine Learning and Neurosurgical Outcome Prediction: A Systematic Review, World Neurosurgery, 109 (2018) 476-486.e471.
[9] A.M. Bur, A. Holcomb, S. Goodwin, J. Woodroof, O. Karadaghy, Y. Shnayder, K. Kakarala, J. Brant, M. Shew, Machine learning to predict occult nodal metastasis in early oral squamous cell carcinoma, Oral Oncology, 92 (2019) 20-25.
[10] J. Zhi, J. Sun, Z. Wang, W. Ding, Support vector machine classifier for prediction of the metastasis of colorectal cancer, International journal of molecular medicine, 41 (2018) 1419-1426.
[11] P. Azimi, H.R. Mohammadi, E.C. Benzel, S. Shahzadi, S. Azhari, A. Montazeri, Artificial neural networks in neurosurgery, Journal of Neurology, Neurosurgery & Psychiatry, 86 (2015) 251.
[12] J. Faradmal, A.R. Soltanian, G. Roshanaei, R. Khodabakhshi, A. Kasaeian, Comparison of the performance of log-logistic regression and artificial neural networks for predicting breast cancer relapse, Asian Pac J Cancer Prev, 15 (2014) 5883-5888.
[13] E. Saus, A. Brunet-Vega, S. Iraola-Guzmán, C. Pegueroles, T. Gabaldón, C. Pericay, Long non-coding RNAs as potential novel prognostic biomarkers in colorectal cancer, Frontiers in genetics, 7 (2016) 54.
[14] I. Garajová, M. Ferracin, E. Porcellini, A. Palloni, F. Abbati, G. Biasco, G. Brandi, Non-coding RNAs as predictive biomarkers to current treatment in metastatic colorectal cancer, International journal of molecular sciences, 18 (2017) 1547.
[15] F. Schmid, Q. Wang, M. Huska, M. Andrade-Navarro, M. Lemm, I. Fichtner, M. Dahlmann, D. Kobelt, W. Walther, J. Smith, SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival, Oncogene, 35 (2016) 5942-5952.
[16] A. Biglarian, E. Bakhshi, M.R. Gohari, R. Khodabakhshi, Artificial neural network for prediction of distant metastasis in colorectal cancer, Asian Pacific Journal of Cancer Prevention, 13 (2012) 927-930.
[17] S. Rajagopalan, E.O. Long, KIR2DL4 (CD158d): an activation receptor for HLA-G, Frontiers in immunology, 3 (2012) 258.
[18] T.R. Kataoka, C. Ueshima, M. Hirata, S. Minamiguchi, H. Haga, Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis, International Journal of Molecular Sciences, 21 (2020) 954.
[19] I. Zidi, N.B. Amor, HLA-G as predisposing for metastasis, Medical hypotheses, 77 (2011) 134-139.
[20] D.M. Ferns, A.M. Heeren, S. Samuels, M.C. Bleeker, T.D. de Gruijl, G.G. Kenter, E.S. Jordanova, Classical and non-classical HLA class I aberrations in primary cervical squamous-and adenocarcinomas and paired lymph node metastases, Journal for immunotherapy of cancer, 4 (2016) 78.
[21] L.M. Nunes, F.M. Ayres, I.C.M. Francescantonio, V.A. Saddi, M.A.G. Avelino, R.d.C.G. Alencar, R.C.d. Silva, A.J. Meneghini, I.J. Wastowski, Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer, Human Immunology, 74 (2013) 447-451.
[22] M. Swets, M.H. König, A. Zaalberg, N.G. Dekker-Ensink, H. Gelderblom, C.J.H. van de Velde, P.J. van den Elsen, P.J.K. Kuppen, HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases, Human Immunology, 77 (2016) 773-779.
[23] A. Lin, W.-H. Yan, Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy, Molecular Medicine, 21 (2015) 782-791.
[24] C. Ueshima, T.R. Kataoka, M. Hirata, A. Furuhata, E. Suzuki, M. Toi, T. Tsuruyama, Y. Okayama, H. Haga, The killer cell Ig-like receptor 2DL4 expression in human mast cells and its potential role in breast cancer invasion, Cancer immunology research, 3 (2015) 871-880.
[25] A. Mitchell, S.L. Hasanali, D.S. Morera, R. Baskar, X. Wang, R. Khan, A. Talukder, C.S. Li, M. Manoharan, A.R. Jordan, A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients, Cancer Biomarkers, (2019) 1-11.
[26] Y. Itatani, K. Kawada, S. Inamoto, T. Yamamoto, R. Ogawa, M.M. Taketo, Y. Sakai, The role of chemokines in promoting colorectal cancer invasion/metastasis, International journal of molecular sciences, 17 (2016) 643.
[27] A. Zipin-Roitman, T. Meshel, O. Sagi-Assif, B. Shalmon, C. Avivi, R.M. Pfeffer, I.P. Witz, A. Ben-Baruch, CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells, Cancer Research, 67 (2007) 3396.
[28] R. Tokunaga, W. Zhang, M. Naseem, A. Puccini, M.D. Berger, S. Soni, M. McSkane, H. Baba, H.-J. Lenz, CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy, Cancer Treatment Reviews, 63 (2018) 40-47.
[29] O. Grip, S. Janciauskiene, Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease, PLoS One, 4 (2009) e5263-e5263.
[30] G. Ferreira, A. Teixeira, E. Sato, Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus, Lupus, 19 (2010) 927-934.
[31] M. Zhou, J. Zheng, J. Bi, X. Wu, J. Lyu, K. Gao, Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin, Oncology letters, 15 (2018) 1985-1992.
[32] K. Gumireddy, A. Li, A.V. Kossenkov, M. Sakurai, J. Yan, Y. Li, H. Xu, J. Wang, P.J. Zhang, L. Zhang, L.C. Showe, K. Nishikura, Q. Huang, The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis, Nature Communications, 7 (2016) 10715.
[33] M. Vithlani, M. Terunuma, S.J. Moss, The dynamic modulation of GABAA receptor trafficking and its role in regulating the plasticity of inhibitory synapses, Physiological reviews, 91 (2011) 1009-1022.
[34] H. Azuma, T. Inamoto, T. Sakamoto, S. Kiyama, T. Ubai, Y. Shinohara, K. Maemura, M. Tsuji, N. Segawa, H. Masuda, γ-Aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism, Cancer research, 63 (2003) 8090-8096.
[35] P.H. Thaker, K. Yokoi, N.B. Jennings, Y. Li, R.B. Rebhun, D.L. Rousseau Jr, D. Fan, A.K. Sood, Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal, Cancer biology & therapy, 4 (2005) 753-758.
[36] L. Liu, C. Yang, J. Shen, L. Huang, W. Lin, H. Tang, W. Liang, W. Shao, H. Zhang, J. He, GABRA3 promotes lymphatic metastasis in lung adenocarcinoma by mediating upregulation of matrix metalloproteinases, Oncotarget, 7 (2016) 32341.
[37] C. Stock, A. Schwab, Ion channels and transporters in metastasis, Biochimica et Biophysica Acta (BBA) - Biomembranes, 1848 (2015) 2638-2646.
[38] S. Martial, Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis, American Journal of Physiology-Cell Physiology, 310 (2016) C710-C727.
[39] M.B. Djamgoz, R.C. Coombes, A. Schwab, Ion transport and cancer: from initiation to metastasis, in, The Royal Society, 2014.
[40] C.L. Dixon, N.L. Harrison, J.W. Lynch, A. Keramidas, Zolpidem and eszopiclone prime α1β2γ2 GABAA receptors for longer duration of activity, British journal of pharmacology, 172 (2015) 3522-3536.
[41] S.V. Fox, A.L. Gotter, S.J. Tye, S.L. Garson, A.T. Savitz, J.M. Uslaner, J.I. Brunner, P.L. Tannenbaum, T.P. McDonald, R. Hodgson, Quantitative electroencephalography within sleep/wake states differentiates GABA A modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats, Neuropsychopharmacology, 38 (2013) 2401-2408.